Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Caribou has initiated the GALLOP Phase 1 clinical trial, an open-label, multicenter clinical trial designed to evaluate a single infusion of CB-010 in adult patients with LN and ERL. CB-011, a ...

Recent advancements in genetic research are proving instrumental in the conservation of endangered species. Scientists are ...

The revolution in artificial intelligence (AI) and genetic engineering represents an unprecedented turning point in human ...

Gene editing involves precise changes in DNA sequences using enzymes, revolutionizing medical, agricultural, and research ...

This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...

Intellia Therapeutics (NTLA) stock falls, sending its gene editing rivals lower, as Wall Street reacts to its latest layoff ...

Imagine a world where the genetic code is as easy to edit as a simple copy-and-paste. This is the reality of CRISPR, a ...

Intellia Therapeutics, a US gene editing company developing CRISPR-based therapies, announced late Thursday its strategic ...

CRISPR-Cas9 pioneer presented with National Medal of Technology and Innovation in White House awards ceremony.

Researchers unveil how biological sex influences brain aging, revealing genetic, hormonal, and molecular mechanisms behind ...

Jennifer Doudna, a UC Berkeley biochemist who shared the 2020 Nobel Prize in Chemistry for the invention of CRISPR-Cas9 ...